**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 29615**

**Manuscript Type:** **Original Article**

***Retrospective Study***

**Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C**

Yamagiwa S *et al.* TVR- and SMV-based therapies for older patients

**Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Hiroto Wakabayashi, Shogo Ohkoshi, Takashi Tsukishiro, Toru Takahashi, Toshiaki Watanabe, Shuji Terai**

**Satoshi Yamagiwa**, **Shuji Terai**, Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan

**Toru Ishikawa,** Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata 950-1104, Japan

**Nobuo Waguri,** Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1197, Japan

**Soichi Sugitani,** Department of Gastroenterology and Hepatology, Tachikawa General Hospital, Nagaoka 940-8621, Japan

**Hiroto Wakabayashi,** Department of Gastroenterology and Hepatology, Takeda General Hospital, Aizuwakamatsu 965-8585, Japan

**Shogo Ohkoshi,** Department of Internal Medicine, Nippon Dental University Medical Hospital, Niigata 951-8580, Japan

**Takashi Tsukishiro,** Department of Internal Medicine, Itoigawa General Hospital, Itoigawa 941-8502, Japan

**Toru Takahashi,** Department of Internal Medicine, Uonuma Hospital, Ojiya 947-0028, Japan

**Toshiaki Watanabe,** Watanabe Clinic, Sanjyo 955-0845, Japan

**Author contributions**: Yamagiwa S, Ishikawa T, Waguri N and Terai S contributed to study conception and design; Yamagiwa S, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, and Watanabe T contributed to data acquisition, data analysis and interpretation; Yamagiwa S and Terai S contributed to drafting the article; all authors contributed to making critical revisions related to important intellectual content of the manuscript; all authors contributed to final approval of the version of the article to be published.

**Supported by** Grants-in-Aid for Scientific Research (C) (to S.Y.) from Japan Society for the Promotion of Science (JSPS), No. 15K08991.

**Institutional review board statement:** The study was reviewed and approved by Niigata University Medical and Dental Hospital Institutional Review Board.

**Informed consent statement:** Written informed consent under institutional review board-approved protocols (approval no. 1474) at Niigata University Medical and Dental Hospital was appropriately obtained from all the individuals enrolled in the study.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Satoshi Yamagiwa, MD, PhD, Associate Professor,** Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan. syamagi@med.niigata-u.ac.jp

**Telephone:** +81-25-2272207

**Fax:** +81-25-2270776

**Received:** August 22, 2016

**Peer-review started:** August 24, 2016

**First decision:** September 27, 2016

**Revised:** December 29, 2016

**Accepted:** January 11, 2017

**Article in press:**

**Published online:**

# Abstract

***AIM***

To evaluate and compare the efficacy and safety of telaprevir (TVR)-and simeprevir (SMV)-based triple therapies in elderly patients, specifically patients aged 66 years or older.

***METHODS***

The present study enrolled 112 and 76 Japanese patients with chronic hepatitis C virus genotype 1b infection who were treated with a 12-week TVR-based or SMV-based triple therapy, respectively, followed by a dual therapy that included pegylated interferon (PegIFN) α and ribavirin (RBV) for 12 weeks. The patients were categorized into two groups according to age as follows: a younger group of patients aged ≤65 years old and an older group of patients aged > 65 years old. Among the patients treated with TVR-based triple therapy, 34 patients were included in the older group. The median ages were 56 years (range: 28-65 years) in the younger group and 69 years (range: 66-81 years) in the older group. Among the patients treated with SMV-based triple therapy, 39 patients were included in the older group. The median ages were 59 years (range: 36-65 years) in the younger group and 71 years (range: 66-86 years) in the older group. The clinical, biochemical and virological data were analyzed before and during treatment.

***RESULTS***

Among the patients treated with the TVR-based triple therapy, no significant difference in the sustained virological response (SVR) was found between the younger (80.8%) and older (88.2%) groups. The SVR rates for patients with the interleukin 28B (IL28B) (rs8099917) TG/GG-genotypes (73.9% and 60.0% in the younger and older groups, respectively) were significantly lower than for patients with the IL28B TT-genotype (86.3% and 92.9%, respectively). The cumulative exposure to RBV for the entire 24-week treatment period (as a percentage of the target dose) was significantly higher in the younger group than in the older group (91.7% vs. 66.7%, respectively, *P* <0.01), but the cumulative exposure to TVR was not significantly different between the younger and older groups (91.6% vs. 81.9%, respectively). A multivariate analysis identified the TT-genotype of IL28B (OR = 8.160; 95%CI: 1.593-41.804, *P* = 0.012) and the adherence of RBV (>60%) (OR = 11.052; 95%CI: 1.160-105-273, *P* = 0.037) as independent factors associated with the SVR. Adverse events resulted in discontinuation of the treatment in 11.3% and 14.7% of the younger and older groups, respectively. Among the patients treated with the SMV-based triple therapy, no significant difference in the SVR rare was found between the younger (81.1%) and older (82.1%) groups. The SVR rates for patients with the IL28B TG/GG-genotypes (77.8% and 64.7% in the younger and older groups, respectively) were significantly lower than for patients with the IL28B TT-genotype (88.2% and 100%, respectively). A multivariate analysis identified the TT-genotype of IL28B as an independent factor associated with the SVR (OR = 9.677; 95%CI: 1.114-84.087, *P* = 0.040). Adverse events resulted in discontinuation of the treatment in 7.0% and 14.3% of patients in the younger and older groups, respectively.

***CONCLUSION***

Both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b chronic hepatitis C. Genotyping of the IL28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.

**Key words:** Telaprevir; Simeprevir; Aged patients; Hepatitis C virus genotype 1b; Interleukin 28B

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We evaluated the efficacy and safety of telaprevir (TVR)-and simeprevir (SMV)-based triple therapies for elderly patients with chronic hepatitis C, especially patients aged 66 years or older, in a real-world clinical setting. In both the TVR and SMV groups, no significant differences in the SVR and adverse events resulting in treatment discontinuation were found between the younger (aged ≤ 65) and older (aged > 65) patients. Both the TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with chronic hepatitis C virus genotype 1b infection. Genotyping of the interleukin-28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.

Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for aged patients with chronic hepatitis C. *World J Hepatol* 2017; In press

# INTRODUCTION

Chronic hepatitis C virus (HCV) infections affect approximately 130-170 million people worldwide and are associated with an increased risk of developing liver cirrhosis and hepatocellular carcinoma (HCC)[1,2]. In Japan, an estimated 1.5-2 million people are infected with HCV[3]. Most of infected patients in Japan are infected with genotype 1 HCV and are older than the infected patients in Europe and the United States[4]. Although older patients with chronic HCV infection have a higher risk of developing HCC than younger patients even at the same liver fibrosis stage[5], older patients have been reported to show poor virological responses to antiviral treatments, especially postmenopausal women[6-8]. Because older patients often have reduced cardiovascular, pulmonary, and renal function and a decreased blood count, they are usually more susceptible to the toxic effects of antiviral treatments, which may lead to a higher rate and severity of adverse events and a poor adherence to the treatment[4]. Therefore, an evaluation of the safety and efficacy of antiviral treatments, especially in elderly patients with chronic HCV infections, is still necessary.

Before the introduction of direct-acting antiviral agents (DAA), pegylated interferon (PegIFN) α and ribavirin (RBV) were the standard of care for HCV genotype 1 infections. However, with the approval of telaprevir (TVR) that is an HCV non-structural (NS) 3/4A protease inhibitor, the optimum treatment regimen for chronic HCV genotype 1 infections was changed to a triple therapy with a protease inhibitor plus PegIFN α and RBV for 24 weeks[9]. The TVR-based triple therapy has achieved an improved sustained virological response (SVR) rate compared to PegIFN monotherapy or PegIFN α plus RBV dual therapy[10,11]. However, the TVR-based triple therapy is associated with an increased rate and severity of adverse events, including pruritus, skin rash, anemia, and anorectal diseases, as well as increased rates of treatment discontinuation compared to patients receiving PegIFNα plus RBV dual therapy[10,11]. Because of the increased risk and severity of adverse events associated with the TVR-based triple therapy, it is difficult to use this therapy in older patients, and, therefore, reports describing the safety and efficacy of TVR-based triple therapy in elderly patients are limited[4].

Simeprevir (SMV) is a second-generation oral HCV NS3/4A protease inhibitor with antiviral activity against HCV genotype 1, 2, 4, 5, and 6 infections[12]. The QUEST 1 and QUEST 2 phase 3 clinical trials demonstrated the SVR rates of 80% and 81%, respectively, in patients treated with SMV-based triple therapy combined with PegIFNα and RBV[13]. In Japan, 4 phase 3 clinical trials (CONCERTO) were conducted, and the SVR rates were 88.6% and 91.7% for treatment-naïve patients; 35.8%, 50.9%, and 38.5% for non-responders; and 89.8% and 96.6% for patients that relapsed[14-16]. Although the SMV-based triple therapy shows a favorable efficacy without inducing severe dermatologic and hematologic toxicities, the safety and efficacy of the SMV-based triple therapy for elderly patients has not yet been fully evaluated. Therefore, in the present study, we aimed to assess the efficacy and safety of TVR- and SMV-based triple therapies in elderly patients, specifically patients aged 66 years or older, in a real-world clinical setting.

# MATERIALS AND METHODS

## Patients

This prospective and multicenter study enrolled 112 and 76 HCV genotype 1b Japanese patients who received 12 weeks of TVR-based and SMV-based triple therapies, respectively, followed by a dual therapy that included PegIFN α and RBV for 12 weeks. Nine hospitals in Niigata, Japan, including Niigata University Hospital, participated in this study. The patients were categorized into two groups according to age as follows: a younger group of patients aged ≤65 years old and an older group of patients aged >65 years old. Among the patients treated with the TVR-based triple therapy, 34 patients were included in the older group. The median ages were 56 years (range: 28-65 years) in the younger group and 69 years (range: 66-81 years) in the older group. Among the patients treated with the SMV-based triple therapy, the older group consists of 39 patients. The median ages were 59 years (range: 36-65 years) in the younger group and 71 years (range: 66-86 years) in the older group. Liver biopsy samples were obtained from 34 (30.6%) and 42 patients (55.2%) in the TVR and SMV groups, respectively. For each sample, the fibrosis stage (F0-4) and activity grade (A0-3) were evaluated according to the Metavir score[17].

According to responses to prior treatments, relapse was defied as undetectable HCV during and at the end of treatment with positive HCV RNA detecting later on. Non-responder was defined as detectable HCV RNA for more than 24 weeks. Patients with decompensated liver cirrhosis, hepatocellular carcinoma, co-infection with hepatitis B virus or human immunodeficiency virus, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, or Wilson’s disease were excluded. Patients with uncontrollable diabetes mellitus, chronic renal failure, depression, and those with a history of alcohol abuse, were also excluded. Information regarding patient profiles was shown in Tables 1 and 2.

## Study design

All patients received a 12-week triple therapy that included either TVR [1500 or 2250 mg/day; the initial dose of TVR was determined by each attending physician based on each patient’s baseline characteristics such as bodyweight (BW)] (the dose of TVR was also reduced by each attending physician based on each patient’s adverse events such as anemia, malaise, and anorexia) (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan) or SMV (100 mg/day) (Sovriad; Janssen Pharmaceutical K.K., Tokyo, Japan) combined with PegIFNα2a (180μg/week) (Pegasys; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) or PegIFNα2b (1.5μg/BW kg/week) (Peg-Intron; MSD, Tokyo, Japan) and RBV (600-1000 mg/day according to BW as follows: <60 kg: 600 mg/day; 60-80 kg: 800 mg/day; >80 kg: 1000 mg/day; if the patient’s hemoglobin was <13 g/dL at the start of therapy, RBV was reduced by 200 mg) (Rebetol; MSD or Copegus; Chugai Pharmaceutical Co., Ltd.), followed by dual therapy of PegIFNα2a or PegIFNα2b with RBV for 12 weeks.

This study was conducted in accordance with the Declaration of Helsinki. The study was reviewed and approved by the Niigata University Medical and Dental Hospital Institutional Review Board. Written informed consent was appropriately obtained from all of the individuals who enrolled in the study according to the institutional review board’s approved protocols (approval no. 1474) at the Niigata University Medical and Dental Hospital.

## Laboratory and safety assessments

Laboratory and safety assessments were performed at initiation of treatment; at treatment weeks 2, 4, 8, 12, 16, 20, and 24; at the end of treatment; and at 12 and 24 weeks after the end of treatment. Data on adverse events were collected, and physical examinations were performed at each visit, if clinically indicated.

## Detection of HCV markers

The detection of HCV viremia was performed using a real-time polymerase chain reaction (PCR) assay (COBAS TaqMan HCV test, Roche Diagnostic, Tokyo, Japan) with a lower limit of quantitation of 15 IU/mL and a linear dynamic range of 1.2-7.8 log IU/mL. The number of amino acid substitutions in the interferon sensitivity-determining region (ISDR) (in the range of 2209-2248 in the HCV NS5A) was determined using a direct sequencing method as reported previously[18]. The core amino acid substitutions at positions 70 and 91 of the HCV genome were determined by direct sequencing as reported previously[19].

## Treatment efficacy

SVR that is defined as undetectable serum HCV RNA at 24 weeks after the end of treatment was successful treatment. Early virological responses during the first 12 weeks of treatment were defined as rapid virological response (RVR), which was undetectable HCV RNA at week 4, and complete early virological response (cEVR), which was undetectable at week 12. End of treatment response (ETR) was defined as undetectable HCV RNA at the end of treatment. Relapse was defined as an ETR response but non-SVR.

## Interleukin 28B single-nucleotide polymorphism

Human genomic DNA was extracted from the peripheral blood. Single-nucleotide polymorphism (SNP) genotyping of the interleukin 28B (IL28B) (rs8099917) gene was performed using the TaqMan allelic discrimination demonstration kit (Applied Biosystems, Foster City, CA). The rs8099917 genotype was classified into the following 2 categories: TT (major genotype) and non-TT (minor genotype, TG or GG).

## Statistical analysis

Continuous data from patients are expressed as the median with the interquartile range. The significance of the differences was analyzed statistically by the Chi-square, Fisher’s exact test, or Mann-Whitney U test, as appropriate, using SPSS software (Ver.18, SPSS Inc., Chicago, IL). To evaluate independent factors for predicting an SVR, variables that reached the *P* <0.1 level in the univariate tests were used as candidate factors in a multivariate logistic regression analysis. In all of the cases, the level of significance was set as *P* value <0.05.

**RESULTS**

## Patient characteristics

The patient characteristics in the TVR group (n = 112) and SMV group (n = 76) are summarized by age in Tables 1 and 2. The analysis of the pretreatment factors revealed that serum albumin, γ-glutamyl-transpeptidase (γGTP), and the estimated glomerular filtration rate (eGFR) in the older patients were significantly lower than those of the younger patients in the TVR group (Table 1). Pretreatment serum chemokine C-X-C motif ligand 10 (CXCL10) levels were not significantly different between the younger (543 pg/ml, range: 118-1218 pg/ml) and older (510 pg/ml, range: 95-1794 pg/ml) groups. In the SMV group, BW, white blood cell count, hemoglobin, serum albumin, and serum alanine aminotransferase (ALT) in the older patients were significantly lower than those of the younger patients (Table 2). No significant differences in the prior treatment response, HCV core 70/91 mutations, or IL28B SNPs were found between the younger and older group in both TVR and SMV groups.

## Virological response and outcome

Figure 1 shows the virological responses by age. RVR, cEVR, ETR, and SVR did not significantly differ between the younger and older patients in the TVR group (60.2% vs. 58.8%, 92.3% vs. 94.1%, 87.2% vs. 88.2%, and 80.8% vs. 88.2%, respectively). Similar to the TVR group, RVR, cEVR, ETR, and SVR did not significantly differ between the younger and older patients in the SMV group (81.1% vs. 92.3%, 94.6% vs. 94.9%, 94.6% vs. 100%, and 81.1% vs82.1%., respectively). In the older patients, SVR did not significantly differ between the TVR and SMV groups, although RVR was significantly higher in the SMV group than in the TVR group (92.3% vs. 58.5%, *P* <0.01).

Figure 2 shows the virological responses according to prior treatment responses. In both the TVR and SMV groups, SVR did not significantly differ between the younger and older patients with the same treatment responses. In the older patients in the SMV group, SVR was significantly lower in the prior non-responders than the prior relapsers (60% vs. 93.8%, *P* = 0.033). Figure 3 shows the virological responses according to IL28B (rs8099917) SNP status. In the TVR group, the SVR rate for the older patients with the IL28B TT-genotype was significantly higher than for the older patients with the IL28B TG/GG-genotypes (92.9% and 60%, *P* = 0.038). In the SMV group, the SVR rate for the older patients with the IL28B TT-genotype was also significantly higher than for the older patients with the IL28B TG/GG-genotypes (100% and 64.7%, *P* <0.01).

## Safety and tolerability

Treatment tolerability was summarized in Tables 3 and 4. In the TVR group, adverse events resulted in treatment discontinuation in 16.7% (13/78 cases) and 11.8% (4/34 cases) of patients in the younger and older groups, respectively. Although a greater number of older patients in the TVR group was treated with the lower initial dose of TVR (1500mg/day) than the younger patients (*P* <0.01)[20], 9 patients (26.4%) discontinued TVR because of adverse events (four patients experienced skin rush, four patients experienced anemia, and one patient experienced renal dysfunction). However, the rate of discontinuation of TVR did not significantly differ between the younger and older patients (Table 3). The cumulative exposure to RBV for the whole 24-week treatment period (as a percentage of the target dose) was significantly higher in the younger patients than in the older patients (79.3±26.2% vs. 62.7±25.3%, *P* <0.01), but the cumulative exposure to TVR was not significantly different between the younger and older patients (88.8±22.8% vs. 83.5±25.5%, *P* = 0.103). Conversely, SMV was not discontinued in either the younger or older patients, although the rate of discontinuation of RBV was significantly higher in the older patients than the younger patients in the SMV group (58.9% vs. 29.7%, *P* = 0.012) because of anemia. Adverse events resulted in treatment discontinuation in 8.1% (3/37 cases) and 7.6% (3/39 cases) of patients in the younger and older groups, respectively.

## Predictive factors correlated with SVR24

To identify pretreatment and treatment factors that contribute to SVR, univariate and multivariate analyses were performed in the TVR and SMV groups including the following variables: gender, age, body mass index, baseline HCV viral load, serum ALT, hemoglobin, platelet counts, IL28B SNP, initial dose of TVR, TVR/BW (mg/kg/day), SMV/BW (mg/kg/day), dose reduction of treatments, and RVR (Tables 5 and 6). In the TVR group, the IL28B SNP significantly correlated with SVR according to the univariate analysis. A multivariate logistic regression analysis identified the IL28B TT-genotype (OR = 8.160; 95%CI: 1.593-41.804, *P* = 0.012) and the adherence of RBV (>60%) (OR = 11.052; 95%CI: 1.160-105.273, *P* = 0.037) as independent factors associated with the SVR (Table 5). In the SMV group, the IL28B SNP and the absence of a dose reduction in PegIFN significantly correlated with SVR according to the univariate analysis. In the multivariate logistic regression analysis, the independent factors associated with the SVR were IL28B TT-genotype (OR = 9.677; 95%CI: 1.114-84.087, P = 0.040) and the absence of a dose reduction in PegIFN (OR = 6.557; 95%CI: 1.328-32.377, *P* = 0.021) (Table 6).

# DISCUSSION

In this study, we evaluated and compared the efficacy and safety of TVR- and SMV-based triple therapies in combination with PegIFN and RBV in elderly Japanese patients with chronic hepatitis C (CHC), specifically patients aged 66 years or older. The rate of SVR did not differ significantly between younger and older patients in either the TVR or the SMV groups. Among the older patients who were more difficult to treat, more patients carrying the IL28B TG/GG genotypes and prior non-responders were enrolled in the SMV group than the TVR group. However, the rate of SVR did not differ significantly between the TVR and SMV group, although the rates of RVR and relapse were significantly higher in the SMV group than the TVR group. When we performed univariate analyses of factors associated with SVR in all the enrolled patients, we did not find any significance in the type of treatment (TVR vs. SMV) (odds ratio: 1.115, 95%CI: 0.415-3.192, *P* = 0.787). Ogawa *et al.* reported that the rates of SVR were similar for patients with HCV genotype 1b who were treated with TVR- and SMV-based triple therapies, although patients treated with TVR-based triple therapy had more frequent severe adverse events than those treated with SMV-based triple therapy[21]. In this study, the rate of adverse events that resulted in treatment discontinuation did not differ between the younger and older patients in either the TVR or the SMV group, although a higher frequency and severity of adverse events have been reported in patients treated with TVR-based triple therapy compared to patients treated with PegIFN and RBV dual therapy[10,11]. We found that both TVR- and SMV-based triple therapy were effective and tolerable among older patients aged 66 years or older.

In Japan, an estimated 1.5-2 million people are infected with HCV, and these patients are older than those infected in Europe and the United States[3,22]. However, previous studies describing the safety and efficacy of TVR- and SMV-based triple therapies, especially in elderly patients with CHC, are limited. One of the reasons may be that the inclusion criteria for clinical trials were usually set to a maximum age of 65 years[11,23]. Furusyo *et al.* reported that there were no differences in the efficacy, frequency and severity of adverse events between patients aged >60 years and those aged ≤60 years who were treated with TVR-based triple therapy[4]. Consistent with our study, they reported that a multivariate analysis revealed that the IL28B TT-genotype and the achievement of RVR were independent factors associated with SVR. Although the decrease in hemoglobin was significantly higher in patients aged >60 years compared to younger patients aged ≤60 years, the rate of adverse events that resulted in treatment discontinuation was similar between the two groups[4]. Abe *et al.* also reported that in patients treated with TVR-based triple therapy, the SVR rate in patients aged >65 years was similar to that of patients aged ≤65 years and that there was no notable increase of the rate of treatment discontinuation[23]. In our study, the rate of adverse events that resulted in treatment discontinuation in the older patients was lower in the SMV group than in the TVR group, but the difference was not statistically significant. However, considering the risk of higher frequency and severity of adverse events associated with TVR-based triple therapy, we recommend the use of SMV rather than TVR.

The IL28B SNP genotype had a limited impact on the SVR rate with triple therapy in treatment-experienced patients[24], and the strength of the association between the IL28B genotype and the treatment outcome was attenuated in the triple therapy compared to the dual therapy[23,25]. In the present study, the IL28B SNP genotype displayed a striking influence on the outcome of both TVR- and SMV-based triple therapy, especially in older patients. In the older patients carrying the IL28B TT-genotype, the rates of SVR were 92.9% and 100% in the TVR and SMV groups, respectively. In contrast, in the older patients carrying the IL28B TG or GG-genotype, the rates of SVR were significantly decreased to 60% and 64.7% in the TVR and SMV groups (*P* = 0.038 and *P* <0.01), respectively. Although the substitutions in the core aa70 of the HCV genotype 1b were reported to be important predictors of the efficacy of dual therapy and triple therapy[26,27], our study revealed that the substitutions in the HCV core aa70 were not associated with the achievement of SVR (data not shown). This discrepancy may be explained by the differences in the study population, as our study consisted of a relatively higher number of aged patients. We also measured serum CXCL10 in patients treated with TVR-based triple therapy because previous studies have reported that pretreatment serum CXCL10 concentrations were associated with early virological response and treatment efficacy in patients treated with this therapy[28,29]. However, we did not confirm the utility of pretreatment CXCL10 concentrations as a predictor of virological response in patients treated with TVR-based triple therapy.

The present study has a number of limitations. First, the sample size might have provided inadequate statistical power to detect definitive differences between the SVR and no-SVR data in both the older and younger patients. However, the best of our knowledge, this is the first study to compare the efficacy and safety of TVR- and SMV-based triple therapies for elderly patients aged 66 years or older. Second, we only investigated Japanese patients with the HCV genotype 1b. Among the Japanese population, the favorable IL28B SNP is found in the majority of the population (approximately 75%)[4]. Therefore, our results may not be generalizable to other racial cohorts. Third, the older patients who enrolled in the study did not have any severe baseline complications, such as renal and hematological diseases. Therefore, the conclusions drawn regarding the safety of triple therapies may be limited. However, we believe that our selection of older patients for the triple therapies was appropriate and acceptable. Therefore, our findings regarding the absence of severe adverse events, even in the older patients, are important.

Treatment for CHC has been changing worldwide[30,31], and IFN-free DAA combination therapies are now available in Japan. Although the majority of CHC patients are usually treated with IFN-free DAA combination therapies, PegIFN and RBV-based therapy may still have utility in a small number of patients who do not show a favorable effect after the treatment with IFN-free DAA therapies. Moreover, considering the effect of preventing HCC by an eradication of HCV, long-term prevention of HCC has been shown only through the use of IFN-based therapies thus far[32,33]. Therefore, we believe that the present study will provide useful information regarding antiviral treatment for older patients with CHC.

In conclusion, we found that both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b CHC. The IL28B genotype indicates a potential to achieve SVR in these difficult-to-treat older patients.

# COMMENTS

## Background

In Japan, an estimated 1.5-2 million people are infected with hepatitis C virus (HCV), and these patients are older than those infected in Europe and the United States. However, previous studies describing the safety and efficacy of telaprevir (TVR)- and simeprevir (SMV)-based triple therapies, especially in elderly patients with chronic HCV infections, are limited.

## Research frontiers

The patients were categorized into two groups according to age as follows: a younger group of patients aged ≤65 years old and an older group of patients aged >65 years old. The rate of sustained virological response (SVR) did not significantly differ between the younger and older patients in both the TVR and SMV groups. The rate of SVR did not significantly differ between the TVR and SMV group, although the rate of rapid virological response (RVR) was significantly higher in the SMV group than the TVR group. The rate of adverse events resulted in treatment discontinuation did not differ between the younger and older patients in both TVR and SMV group, although a higher frequency and severity of adverse events has been reported in patients treated with TVR-based triple therapy compared to patients treated with PegIFN and RBV dual therapy.

## Innovations and breakthrough

In this study, we found that both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b CHC. The IL28B genotype indicates a potential to achieve SVR in these difficult-to-treat elderly patients.

## Applications

Treatment for CHC has been changing worldwide, and interferon (IFN)-free direct-acting antiviral agents (DAA) combination therapies are now available in. Although the majority of CHC patients are usually treated with IFN-free DAA combination therapies, pegylated interferon (PegIFN) α and ribavirin (RBV)-based therapy may still have utility in a small number of patients who do not show a favorable effect after the treatment with IFN-free DAA therapies. Importantly, HCV mutants that are resistant to multiple IFN-free DAA therapies have been shown to be sensitive to IFN-based therapies. Moreover, considering the effect of preventing HCC by an eradication of HCV, long-term prevention of HCC has been shown only through the use of IFN-based therapies thus far. Therefore, we believe that the present study will still provide useful information regarding antiviral treatment for older patients with CHC.

## Terminology

TVR: An HCV non-structural 3/4A (NS3/4A) protease inhibitor. SMV: A second-generation oral HCV NS3/4A protease inhibitor with antiviral activity against HCV genotype 1, 2, 4, 5, and 6 infections.

## Peer-review

## The manuscript is well written and it is clear.

# REFERENCES

1. **Seeff LB**, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. *N Engl J Med* 1992; **327**: 1906-1911 [PMID: 1454085 DOI: 10.1056/NEJM199212313272703]
2. **Mohd Hanafiah K**, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013; **57**: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
3. **Namiki I**, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). *Hepatol Res* 2010; **40**: 347-368 [PMID: 20394674]
4. **Furusyo N**, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. *J Hepatol* 2013; **59**: 205-212 [PMID: 23542346 DOI: 10.1016/j.jhep.2013.03.020]
5. **Asahina Y**, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. *Hepatology* 2010; **52**: 518-527 [PMID: 20683951 DOI: 10.1002/hep.23691]
6. **Zeuzem S**. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? *Ann Intern Med* 2004; **140**: 370-381 [PMID: 14996679]
7. **Honda T**, Katano Y, Shimizu J, Ishizu Y, Doizaki M, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. *Liver Int* 2010; **30**: 527-537 [PMID: 19523048 DOI: 10.1111/j.1478-3231.2009.02064.x]
8. **Furusyo N**, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, Ikezaki H, Hiramine S, Mukae H, Toyoda K, Taniai H, Okada K, Kainuma M, Kajiwara E, Hayashi J. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. *J Hepatol* 2012; **57**: 1186-1192 [PMID: 22889955 DOI: 10.1016/j.jhep.2012.08.003]
9. **Reddy KR**, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. *Lancet Infect Dis* 2015; **15**: 27-35 [PMID: 25482330 DOI: 10.1016/S1473-3099(14)71002-3]
10. **Jacobson IM**, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; **364**: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
11. **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; **364**: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
12. **Fried MW**, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. *Hepatology* 2013; **58**: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]
13. **Jacobson IM**, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet* 2014; **384**: 403-413 [PMID: 24907225 DOI: 10.1016/S0140-6736(14)60494-3]
14. **Hayashi N**, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. *J Hepatol* 2014; **61**: 219-227 [PMID: 24727123]
15. **Izumi N**, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. *J Gastroenterol* 2014; **49**: 941-953 [PMID: 24626851 DOI: 10.1007/s00535-014-0949-8]
16. **Kumada H**, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. *Hepatol Res* 2015; **45**: 501-513 [PMID: 24961662 DOI: 10.1111/hepr.12375]
17. **Bedossa P**, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; **24**: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]
18. **Enomoto N**, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996; **334**: 77-81 [PMID: 8531962 DOI: 10.1056/NEJM199601113340203]
19. **Akuta N**, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005; **48**: 372-380 [PMID: 16024941 DOI: 10.1159/000086064]
20. **Hara T**, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. *J Med Virol* 2013; **85**: 1746-1753 [PMID: 23861088 DOI: 10.1002/jmv.23673]
21. **Ogawa E**, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. *J Gastroenterol Hepatol* 2015; **30**: 1759-1767 [PMID: 26095167 DOI: 10.1111/jgh.13016]
22. **Yoshizawa H**, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. *Intervirology* 2006; **49**: 7-17 [PMID: 16166783]
23. **Abe H**, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. *Gastroenterol Res Pract* 2014; **2014**: 549709 [PMID: 25197269 DOI: 10.1155/2014/549709]
24. **Pol S**, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR, Focaccia R, Horban A, Pockros PJ, Van Heeswijk RP, De Meyer S, Luo D, Botfield M, Beumont M, Picchio G. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. *J Hepatol* 2013; **58**: 883-889 [PMID: 23321318 DOI: 10.1016/j.jhep.2012.12.023]
25. **Holmes JA**, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? *J Viral Hepat* 2012; **19**: 677-684 [PMID: 22967098 DOI: 10.1111/jvh.12003]
26. **Akuta N**, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. *Intervirology* 2012; **55**: 231-241 [PMID: 21734353 DOI: 10.1159/000328327]
27. **Akuta N**, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. *Hepatology* 2010; **52**: 421-429 [PMID: 20648473 DOI: 10.1002/hep.23690]
28. **Matsuura K**, Watanabe T, Iijima S, Murakami S, Fujiwara K, Orito E, Iio E, Endo M, Kusakabe A, Shinkai N, Miyaki T, Nojiri S, Joh T, Tanaka Y. Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. *Hepatol Res* 2014; **44**: 1208-1216 [PMID: 24372894 DOI: 10.1111/hepr.12294]
29. **Nishikawa H**, Enomoto H, Nasu A, Aizawa N, Saito M, Tamori A, Kawada N, Kimura T, Osaki Y, Nishiguchi S. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. *Hepatol Res* 2014; **44**: E397-E407 [PMID: 24628684 DOI: 10.1111/hepr.12326]
30. **Webster DP**, Klenerman P, Dusheiko GM. Hepatitis C. *Lancet* 2015; **385**: 1124-1135 [PMID: 25687730]
31. **Fujii H**, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. *World J Hepatol* 2015; **7**: 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841]
32. **Cardoso AC**, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol* 2010; **52**: 652-657 [PMID: 20346533 DOI: 10.1016/j.jhep.2009.12.028]
33. **Ikeda K**, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 1999; **29**: 1124-1130 [PMID: 10094956]

**P-Reviewer:** Conti B, Kawakami Y, Larrubia JR, Liang XS **S-Editor:** Kong JX **L-Editor: E-Editor:**

****

**Figure 1 Rates of virological responses to telaprevir and simeprevir by age.** Percentages indicate the proportion of patients with undetectable serum hepatitis C virus (HCV) RNA levels. Patient numbers are shown in parenthesis. RVR, rapid virological response; cEVR, complete early virological response; ETR, end of treatment response; SVR24, sustained virological response defined as undetectable serum HCV RNA at 24 wk after the end of treatment.

****

**Figure 2 Rates of sustained virological response to telaprevir and simeprevir by prior treatment responses.** Percentages indicate the proportion of patients with undetectable serum hepatitis C virus (HCV) RNA levels at 24 weeks after the end of treatment. Patient numbers are shown in parenthesis. NR, non-responders. \**P* = 0.033 (compared to relapsers in the older patients).



**Figure 3 Rates of sustained virological response to telaprevir and simeprevir by interleukin 28B single-nucleotide polymorphism.** Percentages indicate the proportion of patients with undetectable serum hepatitis C virus RNA levels at 24 weeks after the end of treatment. Patient numbers are shown in parenthesis. TT, interleukin 28B (IL28B) (rs8099917) TT-genotype; non-TT, IL28B TG/GG-genotypes \**P* = 0.038 (compared to older patients with the IL28B TT-genotype). \*\**P* = 0.005 (compared to older patients with the IL28B TT-genotype).

**Table 1 Patient characteristics by age (telaprevir)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factors (Median, range)** | **Patients aged < 66** | **Patients aged ≥ 66** | ***P* value** |
| *n* | 78 | 34 |  |
| Gender, *n* (Male/Female) | 41/37 | 20/14 | 0.680 |
| Age (years) | 56 (28-65) | 69 (66-81) | <0.001 |
| Body weight (kg) | 61.1 (35.0-97.4) | 57.8 (41.0-74.8) | 0.105 |
| Body mass index (kg/m2) | 22.7 (15.8-32.2) | 22.9 (17.9-28.9) | 0.892 |
| Baseline HCV-RNA (log IU/mL) | 6.7 (3.9-7.7) | 6.7 (3.1-7.8) | 0.766 |
| White blood cell (/mm3) | 5000 (1900-8720) | 4500 (2700-7700) | 0.245 |
| Hemoglobin (g/dL) | 14.0 (9.1-18.6) | 13.5 (9.5-16.3) | 0.121 |
| Platelets (× 104 /mm3) | 15.8 (6.5-28.7) | 13.4 (8.3-29.0) | 0.068 |
| Albumin (mg/dL) | 4.1 (2.7-5.9) | 3.9 (2.4-4.4) | 0.007 |
| AST (IU/L) | 40 (17-249) | 45 (20-163) | 0.909 |
| ALT (IU/L) | 48 (15-278) | 38 (15-189) | 0.486 |
| γ-GTP (IU/L) | 39 (11-717) | 25 (11-144) | 0.034 |
| Serum creatinine (mg/dL) | 0.7 (0.4-1.2) | 0.8 (0.4-1.0) | 0.036 |
| Estimated GFR (mL/min) | 79.0 (44.0-134.0) | 71.5 (39.0-101.9) | 0.006 |
| Prior treatment response, n (naïve/relapse/non-responder) | 45/26/7 | 15/15/4 | 0.403 |
| Liver histology (F0-2/3-4/ND) | 21/6/51 | 4/3/27 | 0.348 |
| IL28B SNP (rs8099917), *n* (TT/non-TT/ND) | 51/22/5 | 28/5/1 | 0.235 |
| HCV ISDR, n (0 /1-3 /4-/NT) | 32/26/6/14 | 15/10/2/7 | 0.955 |
| HCV Core 70, n(Wild/Mutant/ND) | 46/18/14 | 18/10/6 | 0.751 |
| HCV Core 91, n(Wild/Mutant/ND) | 42/22/14 | 19/9/6 | 1 |
| Serum CXCL10 (pg/mL) | 510 (95-1794) | 543 (118-1218) | 0.445 |
| GFR: Glomerular filtration rate; IL28B SNP: Interleukin-28B single nucleotide polymorphism; ND: Not determined; ISDR: Interferon sensitivity-determining region; HCV Core 70 or 91: At position 70 or 91 of the HCV core protein; CXCL10: Chemokine (C-X-C motif) ligand 10. |

|  |
| --- |
| **Table 2 Patient characteristics by age (simeprevir)** |
| **Factors (Median, range)** | **Patients aged <66** | **Patients aged ≥66** | ***P* value** |
| *n* | 37 | 39 | - |
| Gender, n (%) (Male/Female) | 19/18 (48.6%) | 14/25 (64.1%) | 0.123 |
| Age (yr) | 59 (36-65) | 71 (66-86) | <0.001 |
| Body weight (kg) | 62.0 (39.8-94.0) | 56.0 (37.5-76.6) | 0.011 |
| Body mass index (kg/m2) | 22.8 (17.2-30.3) | 22.7 (17.8-32.1) | 0.287 |
| Baseline HCV-RNA (log IU/mL) | 6.7 (5.4-7.8) | 6.6 (4.7-7.6) | 0.631 |
| White blood cells (/mm3) | 4620 (2600-7800) | 4300 (2400-8100) | 0.010 |
| Hemoglobin (g/dL) | 13.8 (11.0-16.7) | 13.1 (9.8-16.8) | <0.001 |
| Platelets (×104/mm3) | 16.4 (8.7-28.8) | 16.3 (7.3-31.7) | 0.291 |
| Albumin (mg/dL) | 4.2 (2.8-4.8) | 4.0 (3.1-4.6) | 0.002 |
| AST (IU/L) | 45 (21-159) | 34 (19-128) | 0.056 |
| ALT (IU/L) | 42 (16-316) | 29 (12-112) | 0.006 |
| γ-GTP (IU/L) | 29 (13-260) | 27 (9-171) | 0.388 |
| Serum creatinine (mg/dL) | 0.70 (0.44-1.01) | 0.70 (0.42-1.36) | 0.689 |
| Estimated GFR (mL/min) | 78.7 (50.0-112.6) | 77.4 (41.3-109.0) | 0.221 |
| Prior treatment response, *n* (naïve/relapse/non-responder) | 20/10/7 | 13/16/10 | 0.197 |
| Liver histology (F0-2/3-4/ND) | 12/6/19 | 19/5/15 | 0.483 |
| IL28B SNP (rs8099917), *n*(TT/non-TT/ND) | 17/19/1 | 18/17/4 | 1 |
| HCV ISDR, *n* (0/1-3/4-/ND) | 9/13/5/10 | 11/12/2/14 | 0.044 |
| HCV Core 70, *n*(Wild/Mutant/ND) | 17/13/7 | 15/8/16 | 1 |
| HCV Core 91, *n*(Wild/Mutant/ND) | 18/12/7 | 18/5/16 | 0.385 |
| GFR: Glomerular filtration rate; IL28B SNP: Interleukin-28B single nucleotide polymorphism; ND: Not determined; ISDR: Interferon sensitivity-determining region; HCV Core 70 or 91: At position 70 or 91 of the HCV core protein. |

|  |
| --- |
| **Table 3 Treatment tolerability (telaprevir)** |
|  | Patients aged <66 | Patients aged ≥ 66 | *P* value |
| Initial doses (Median, range) |  |  |  |
| PEG-IFN/BW (μg/kg/week) | 1.48 (0.98-2.00) | 1.49 (1.15-1.87) | 0.859 |
| TVR/BW (mg/kg/day) | 33.0 (19.2-64.3) | 29.2 (7.5-54.2) | 0.044 |
| TVR (2250 mg/1500 mg/others), *n* | 55/23/0 | 11/21/2 | <0.001 |
| RBV/BW (mg/kg/d) | 11.4 (6.8-20.0) | 11.4 (5.7-28.0) | 0.103 |
| Dose reduction, *n* |  |  |  |
| PEG-IFN | 7 (8.9%) | 6 (17.6%) | 0.209 |
| TVR | 19 (24.3%) | 12 (35.3%) | 0.256 |
| RBV | 40 (51.2%) | 27 (79.4%) | 0.006 |
| Discontinuation, *n* |  |  |  |
| PEG-IFN | 13 (16.7%) | 4 (11.8%) | 0.580 |
| TVR | 12 (15.4%) | 9 (26.5%) | 0.192 |
| RBV | 12 (15.4%) | 7 (20.6%) | 0.585 |
| Adherence, mean ± SD (%) |  |  |  |
| PEG-IFN | 88.2 ± 25.7 | 90.1 ± 19.8 | 0.606 |
| TVR | 88.8 ± 22.8 | 83.5 ± 25.5 | 0.103 |
| RBV | 79.3 ± 26.2 | 62.7 ± 25.3 | **<**0.001 |
|  |

|  |
| --- |
| **Table 4 Treatment tolerability (simeprevir)** |
|  | **Patients aged <66** | **Patients aged ≥66** | ***P* value** |
| Initial doses (Median, range) |  |  |  |
| PEG-IFNα2a (180/90) (μg/wk) | 19/0 | 10/1 | 0.366 |
| PEG-IFNα2b (120/100/80/others)(μg/wk) | 2/16/5/1 | 0/25/5/1 | 0.422 |
| SMV/BW (mg/kg/d) | 1.6 (1.1-2.5) | 1.8 (1.3-2.7) | 0.011 |
| RBV/BW (mg/kg/d) | 11.6 (6.8-17.1) | 12.3 (6.0-20.6) | 0.166 |
| Dose reduction, *n* |  |  |  |
| PEG-IFN | 5 (13.5%) | 6 (15.3%) | 1 |
| SMV | 0 | 0 | 1 |
| RBV | 3 (8.1%) | 6 (15.3% ) | 0.481 |
| Discontinuation, *n* |  |  |  |
| PEG-IFN | 5 (13.5%) | 5 (12.8%) | 1 |
| SMV | 2 (5.4%) | 2 (5.1%) | 1 |
| RBV | 11 (29.7%) | 23 (58.9%) | 0.012 |
| Adherence, mean ± SD (%) |  |  |  |
| PEG-IFN | 93.6 ± 16.8 | 92.3 ± 19.5 | 0.592 |
| SMV | 98.1 ± 7.2 | 93.9 ± 18.1 | 0.079 |
| RBV | 91.0 ± 16.1 | 86.8 ± 20.2 | 0.126 |
|  |

|  |
| --- |
| **Table 5 Univariate and multivariate analysis of factors contributing to SVR24 (telaprevir)** |
| **Factors** | **Univariate analysis** |  | **Multivariate analysis** |
| Odds ratio (95%CI) | *P* value |  | Odds ratio (95%CI) | *P* value |
| Age | 1.012 (0.955-1.072) | 0.689 |  |  |  |
| Gender (Female) | 0.784 (0.262-2.342) | 0.663 |  |  |  |
| Body mass index (kg/m2) | 1.074 (0.875-1.318) | 0.495 |  |  |  |
| Prior treatment response (non-NR) | 3.850 (0.830-17.861) | 0.085 |  |  |  |
| Baseline HCV-RNA(log IU/mL) | 1.264 (0.457-3.495) | 0.652 |  |  |  |
| Baseline ALT (IU/mL) | 1.008 (0.998-1.017) | 0.105 |  |  |  |
| Baseline Platelets(x104/mm3) | 1.017 (0.906-1.142) | 0.775 |  |  |  |
| Baseline Hemoglobin(g/dL) | 1.038 (0.736-1.464) | 0.830 |  |  |  |
| IL28B SNP (TT) | 6.700 (1.826-24.584) | 0.004 |  | 8.160 (1.593-41.804) | 0.012 |
| Initial dose of TVR(2250mg/day) | 2.069 (0.670-6.553) | 0.204 |  |  |  |
| TVR/BW (mg/kg/d) | 0.938 (0.870-1.011) | 0.093 |  |  |  |
| RBV/BW (mg/kg/d) | 0.811 (0.617-1.066) | 0.133 |  |  |  |
| PEG-IFN dose reduction (none) | 2.134 (0.253-17.988) | 0.486 |  |  |  |
| TVR dose reduction (none) | 1.020 (0.281-3.703) | 0.976 |  |  |  |
| RBV dose reduction (none) | 1.548 (0.433-5.525) | 0.501 |  |  |  |
| Adherence of RBV(>60%) | 6.873 (1.784-26.474) | 0.005 |  | 11.052 (1.160-105.273) | 0.037 |
| RVR (none) | 0.88 (0.123-1.216) | 0.104 |  |  |  |
| NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; RVR: Rapid virological response. |

|  |
| --- |
| **Table 6 Univariate and multivariate analysis of factors contributing to SVR24 (simeprevir)** |
| **Factors** | **Univariate analysis** |  | **Multivariate analysis** |
| **Odds ratio (95%CI)** | ***P* value** |  | **Odds ratio (95%CI)** | ***P* value** |
| Age | 0.998 (0.942-1.058) | 0.953 |  |  |  |
| Gender (Female) | 0.330 (0.083-1.314) | 0.116 |  |  |  |
| Body mass index (kg/m2) | 1.164 (0.934-1.450) | 0.175 |  |  |  |
| Prior treatment response(non-NR) | 2.955 (0.811-10.764) | 0.101 |  |  |  |
| Baseline HCV-RNA(log IU/mL) | 0.767 (0.328-1.791) | 0.540 |  |  |  |
| Baseline ALT (IU/mL) | 0.998 (0.985-1.012) | 0.785 |  |  |  |
| Baseline Platelets(x104/mm3) | 1.082 (0.953-1.228) | 0.224 |  |  |  |
| Baseline Hemoglobin(g/dL) | 1.257 (0.827-1.910) | 0.285 |  |  |  |
| IL28B SNP (TT) | 12.593(1.516-104.576) | 0.019 |  | 9.677 (1.114-84.087) | 0.040 |
| SMV/BW (mg/kg/d) | 0.306 (0.054-1.742) | 0.182 |  |  |  |
| RBV/BW (mg/kg/d) | 1.085 (1.138-3.913) | 0.501 |  |  |  |
| PEG-IFN dose reduction(none) | 7.250 (1.712-30.700) | 0.007 |  | 6.557 (1.328-32.377) | 0.021 |
| RBV dose reduction (none) | 1.556 (0.470-5.160) | 0.470 |  |  |  |
| RVR (none) | 0.351 (0.075-1.637) | 0.183 |  |  |  |
| NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; RVR: Rapid virological response. |